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ABSTRACT
Background/Aims: Endoscopic retrograde cholangiopancreatography (ERCP) is used as a curative method for choledocholithiasis, but 
little is known about ERCP for patients with end-stage renal disease (ESRD) on hemodialysis (HD). The aim of the current study was to 
evaluate the efficacy and safety of ERCP for patients with ESRD on HD and to identify the risk factors of ERCP-related bleeding. 
Materials and Methods: The medical records of 61 ESRD patients with choledocholithiasis who underwent ERCP were retrospectively 
investigated with respect to successful bile duct stone removal and procedure-related adverse events such as pancreatitis, bleeding, 
and cholangitis.
Results: For the study subjects, the overall stone removal success rate was 96.7%, and the overall ERCP-related adverse event rate 
was 21.3% (pancreatitis, 4.9%; bleeding, 13.1%; cholangitis, 6.6%). Endoscopic sphincterotomy (EST) was found to be associated with 
hemorrhage (p=0.02), and the occurrence of hemorrhage in patients who underwent EST with or without endoscopic papillary balloon 
dilation (EPBD) was significantly higher than that in patients who underwent EPBD alone (Odds ratio 1.27, 95% confidence interval 
1.075-1.493, p=0.02).
Conclusion: ERCP for ESRD patients was found to be feasible and safe. However, EST was significantly related to hemorrhagic events. 
EPBD reduced the risk of hemorrhage and was as effective as EST in terms of stone removal.
Keywords: Endoscopic retrograde cholangiopancreatography, hemodialysis, bleeding, choledocholithiasis
INTRODUCTION
Gallstone disease is a major cause of morbidity and the 
prevalence of gallstones in the general adult population is 
about 10% (1). However, in contrast to the general adult 
population, the prevalence of gallstone disease in hemo-
dialysis (HD) patients is as much as 30% (2). It is believed 
that increase in bile cholesterol level and cholesterol sat-
uration index in bile by HD is associated with the higher 
prevalence of gallstones in this patient population (3). In 
addition, the gallbladder is innervated by the autonomic 
nervous system, which malfunctions in uremia, and it has 
been suggested gallbladder stasis increases stone forma-
tion (4). Furthermore, since gallstones are present in 15% 
to 20% of patients with common bile duct (CBD) stones 
(5), endoscopic retrograde cholangiopancreatography 
(ERCP) is frequently required for CBD stone removal. 
Generally, patients with end-stage renal disease (ESRD) 
on HD are considered high-risk candidates for invasive 
endoscopic treatments because tissue vulnerability and 
the tendency to bleed increase the risk of tissue pene-
tration. The mechanism responsible for excessive bleed-
ing in patients with HD is still unclear but platelet dys-
functions like impaired platelet adhesiveness and altered 
platelet-vessel wall interactions are believed to play im-
portant roles (6). In addition, the endoscopic procedures 
required for CBD stone removal, such as endoscopic bil-
iary sphincterotomy (EST) and endoscopic papillary bal-
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loon dilatation (EPBD), have substantial bleeding risks 
(7). From this perspective, ERCP should be treated as a 
different entity with high operative risks in patients with 
ESRD on HD. However, no previous study has been con-
ducted on ERCP in this background, although several re-
ports have been issued on clinical outcomes, including 
bleeding risks, of open surgery and other invasive endo-
scopic procedures for patients with ESRD on HD (8, 9).
The aim of the present study was to assess the clinical 
outcomes and safety of ERCP for patients with ESRD on 
HD, especially the bleeding risk associated with ERCP. In 
addition, we also tried to identify the risk factors of pro-
cedure-related bleeding in these patients. 
MATERIALS AND METHODS
Study design and patients
Multi-site retrospective analysis was performed at six 
Korean tertiary institutions. The study protocol was ap-
proved by institutional review boards at all participating 
centers. Consecutive patients with ESRD and choledo-
cholithiasis who underwent ERCP between January 2007 
and December 2017 were enrolled in the study. Inclusion 
criteria were as follows: (1) age >18 years; (2) choledocho-
lithiasis, as demonstrated by retrograde cholangiography; 
(3) deep cannulation of the bile ducts without pre-cutting 
or infundibulotomy; (4) naïve major duodenal papilla sta-
tus; and (5) ESRD with undergoing HD (ESRD was defined 
as described by the Kidney Disease Outcomes Quality 
Initiative (K/DOQI) working group: individuals with kidney 
failure (glomerular filtration rate of <15 mL/min/1.73 m2) 
with signs and symptoms of kidney failure (10)). Exclusion 
criteria were as follows: (1) concurrent coagulopathy (liv-
er cirrhosis or coagulation dysfunction); (2) unsuccessful 
cholangiography; (3) a history of EST or EPBD; and (4) a 
history of gastrointestinal surgery. Medical records were 
retrospectively reviewed, and the following information 
was extracted: clinical characteristics, clinical course, and 
ERCP-related adverse events including bleeding, perfo-
ration and pancreatitis. In addition, we sought to identify 
factors related to procedure-related bleeding, such as the 
duration of HD, time interval between HD and ERCP, use 
of heparin in HD, use of anticoagulation, platelet count, 
and ERCP-related factors. 
ERCP procedure
ERCP was performed using standard duodenoscopes. All 
endoscopic procedures were carried out by one of seven 
endoscopists, who had each performed more than 400 
ERCPs annually over the preceding 10 years. ERCP was 
performed with patients under conscious midazolam and 
meperidine hydrochloride sedation. Protease inhibitors 
(Gabexate mesilate, nafamostat mesilate, or ulinastatin) 
that might affect the occurrence of post-ERCP pan-
creatitis were administered before ERCP at the endos-
copist’s discretion. Briefly, after locating the major duo-
denal papilla, the bile duct was deeply cannulated with 
a 0.035 inch guidewire-loaded catheter (ERCP-Kathter; 
MTW EndosKopie, Wesel, Germany), and a diagnostic 
cholangiogram was obtained. Bile duct and stone diam-
eters were measured on cholangiograms during ERCP. 
EST was performed according to standard guidelines us-
ing conventional pull-type sphincterotomes (11). All ESTs 
were performed using the normal blended current (cut 
45W, coagulation 30W) from an Olympus electrosurgical 
unit (PSD-30). EST length depended on indications, that 
is, small for stent placement or as large as possible for 
choledocholithiasis. For EPBD, a guidewire was passed 
through a diagnostic catheter into the bile duct, and then 
the catheter was removed. When the maximum trans-
verse diameter of the largest stone was ≥10 mm and 
distal CBD diameter was ≥12mm, EPBD was performed 
using a 12-mm balloon catheter (CRE Wireguided dila-
tor; Microvasive; Boston Scientific Corp, Natick, MA) for 
dilation. For smaller stones, an 8-mm balloon catheter 
(Olbert; Microvasive Endoscopy, Boston Scientific Corp., 
Natick, MA) was used for dilation. Balloon catheters were 
passed over a 0.035-inch guidewire (Boston Scientific 
Corp) and placed across the major papilla. Balloons were 
inflated gradually to maximum size by injecting diluted 
contrast using an inflation device (Indeflator; Abbott, 
Santa Clara, CA) under fluoroscopic guidance until they 
were estimated to be adequate for stone removal. After 
waists had disappeared, the balloons were left inflated for 
60 seconds. After EST or EPBD, the stones were extract-
ed using a Dormia basket and/or a retrieval balloon cath-
eter. When stone extraction was impossible, mechanical 
lithotripsy was performed as necessary. Complete stone 
MAIN POINTS
• This study conducted on the medical records of 61 ESRD 
patients with choledocholithiasis who underwent ERCP to 
evaluate the efficacy and safety of ERCP for patients with 
ESRD on HD and to identify the risk factors of ERCP-relat-
ed bleeding. In the results, the clinical outcomes of ERCP for 
stone removal showed satisfactory results. However, ER-
CP-related adverse event rate was high (21.3%), especially 
in bleeding (13.1%).
• In the analysis of bleeding risk factor, EST was significantly 
related to induce bleeding compared with EPBD (Odds ratio 
1.27, 95% confidence interval 1.075-1.493, p=0.02).
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removal was confirmed by the absence of any filling de-
fect by balloon occlusion cholangiography. If stone clear-
ance could not be achieved in the first session, stone re-
moval was re-attempted 2 or 3 days later.
Outcome measures
The outcome measures evaluated were overall procedur-
al success rate and procedure-related adverse events. 
Overall procedural success rate was defined as the rate 
of complete stone retrieval from the CBD after EST and/
or EPBD, irrespective of whether mechanical lithotripsy 
was required or the number of ERCP sessions needed. All 
patients were hospitalized for at least 24 hours after the 
procedure. All adverse events were classified and graded 
according to consensus guidelines with some modifica-
tions (12). Procedure-related ERCP pancreatitis was diag-
nosed when new-onset pancreatitis or increased abdom-
inal pain (lasting >24 hours) associated with an increased 
serum amylase level of >3 times the normal upper limit 
developed the next morning (after ERCP) (13). Bleeding 
was identified when clinical evidence of bleeding, such as 
melena or hematemesis, in association with hemoglobin 
concentration decrease of ≥2 g/dL in the hematolog-
ic results after the procedure was present (14). Delayed 
bleeding that occurred 48 hours after the procedure was 
not measured in the current study. Cholangitis was di-
agnosed as elevated body temperature (>38°C) over 24 
hours with abdominal pain. Perforation was defined by 
the presence of free air or contrast leakage during a ra-
diologic examination.
Statistical Analysis
Continuous variables are presented as means and stan-
dard deviations (SDs). The analysis was performed using 
the chi-squared test or the Fisher exact test for categor-
ical variables and the student t test for continuous vari-
ables. Logistic regression analysis was used to identify 
factors affecting procedure-related bleeding. Statistical 
significance was accepted for p values <0.05, and the 
analysis was conducted using the Statistical Packages for 




In total, 61 patients with ESRD and choledocholithiasis 
were enrolled in the current study. Demographic and clinical 
characteristics are shown in Table 1. The patients included 
36 men and 25 women with mean age 69.7 years (SD, 10.7 
years). The reasons for HD were hypertension (n=21), dia-
betes mellitus (n=35), polycystic kidney disease (n=1), and 
unknown cause (n=4). The mean duration of HD was 49.6 
months (SD, 55.8 months) and mean time from last HD to 
ERCP was 26.1 hours (SD, 18.7 hours). In 43 patients, hepa-
rin had been administered for last HD. Thirty-eight patients 
had received antiplatelet agents and/or anticoagulation 
agents for concomitant cardiovascular disease or diabetes 
mellitus, and ERCPs were performed urgently without dis-
Table 1. Baseline characteristics of the study subjects. 
Value Total (n=61)
Gender (men/women) 36/25
Mean age, year (SD) 69.7 (10.7)
Etiologies for renal failure, n (%)
   Hypertension 21 (34.4)
   Diabetes melitus 35 (57.4)
   Polycystic kidney disease 1 (1.6)
   Unknown cause 4 (6.6)
Mean time interval between HD and ERCP, 
Hour (SD)
26.1 (18.7)
Mean duration of hemodialysis, month (SD) 49.6 (55.8)
The routine schedule of hemodialysis
   Two times a week 8 (13.1)
   Three times a week 53 (86.9)
The use of heparin in last hemodialysis, n (%) 43 (70.5)
The use of anticoagulation medication, n (%)
   Antiplatelet agent (Aspirin, Clopidogrel) 33 (54.1)
   Anticoagulation agent 2 (3.3)
   Antiplatelet and Anticoagulation agent 3 (4.9)
Hematologic result, mean (SD)
   Hemoglobin, g/dL 10.4 (1.4)
   Platelet, 1000/µL 187.7 (99.2)
   Creatinine, mg/dL 5.1 (2.9)
   Prothrombin time, INR 1.1 (0.2)
   aPTT, sec 30.6 (13.5)
   Total bilirubin, mg/dL 2.6 (2.9)
   amylase, IU/L 323.9 (874.9)
   Lipase, IU/L 662.4 (1922.8)
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continuation of these agents. Their medications were dis-
continued for 24-48 hours after the endoscopic procedure 
and re-started if there was no bleeding. 
Bile duct clearance
Deep cannulation into the bile duct was achieved in all pa-
tients, and EST (n=30), EPBD (n=23), or EST with EPBD 
(n=8) resulted in complete bile duct stone removal. CBD 
stones were completely removed in 59 (96.7%) patients; 
in 2 cases, stone removal was unsuccessful due to stone 
impaction. The two patients concerned underwent surgical 
stone removal. The mean number of endoscopic sessions 
required for complete bile duct clearance was 1.2 (range 
1-3), 8 patients required additional ERCP sessions (one 
session in 6 patients and 2 sessions in 2 patients). Mechan-
ical lithotripsy was used in 5 (8.2%) patients (Table 2).
Adverse events
Adverse events occurred in 13 patients (21.3%) after 
ERCP. One patient experienced cholangitis and pancre-
atitis simultaneously. Results are summarized in Table 2.
Hemorrhage
Minor bleeding occurred frequently during the endoscop-
ic procedures, and most minor bleeding was controlled by 
spraying epinephrine solution on the bleeding site and 
by using a balloon tamponade. This minor bleeding was 
not encountered as ERCP-associated hemorrhage. The 
rate of ERCP-associated hemorrhage was 13.1% (n=8). 
Bleeding in 7 of the 8 patients was controlled with en-
doscopic management. To control bleeding, epinephrine 
(1:10,000) was sprayed on the bleeding site and a balloon 
tamponade was initially applied. If these measures failed, 
consecutive injections of epinephrine were administered. 
For exposed vessels, epinephrine was injected around the 
bleeding sites, and exposed vessels were hemoclipped. 
Despite multiple sessions of endoscopic injection ther-
apy including fully covered metal stent insertion, mas-
sive blood transfusion, angiography and intensive care, 
one patient bled to death (Figure 1). An analysis of the 
risk factors of bleeding showed that EST was significantly 
related to hemorrhagic events (P=0.02). Other factors in-
cluding age, gender, use of antiplatelet agents or antico-
agulation agents, HD factors, the number of endoscopic 
sessions, mechanical lithotripsy, and hematologic factors 
were not significantly related to hemorrhage (Table 3).
Pancreatitis and cholangitis
Post-ERCP pancreatitis occurred in three patients 
(4.9%) and was graded as mild; cholangitis occurred in 
four patients (6.6%). All patients with pancreatitis and/or 
cholangitis recovered uneventfully on conservative treat-
ment. None of the patients developed acute cholecystitis 
or perforation. 
EST vs. EPBD
For this analysis, patients were allocated to either of the 
2 groups: an EST group (n=38, comprising EST only and 
EST plus EPBD) and an EPBD group (n=23, EPBD only). 
The overall success rates for complete bile duct clearance 
in the EST and EPBD groups were similar at 94.7% and 
100%, respectively (p=0.52), as were the mean number 
of sessions required for clearance (p=0.69). Mechanical 
lithotripsy was performed in three (7.9%) patients in the 
EST group and in 2 (8.7%) patients in the EPBD group 
(p=0.63). An analysis of the risk factors of hemorrhage 
showed that the type of papillary dilation was associat-
ed with hemorrhage (p=0.02). Hemorrhage occurred in 
5 (16.7%) of the 30 patients who underwent EST alone 
and in 3 (37.5%) of the 8 patients who underwent EST 
plus EPBD. Hemorrhage did not occur in any patient who 
underwent EPBD alone. The occurrence of hemorrhage 
among patients in the EST group was significantly higher 
Table 2. Outcomes and adverse events of ERCP in ESRD patients 
on HD.
Value Total (n=61)
Bile duct clearance 59 (96.7)
Kinds of ERCP procedure, n (%)
   EST 30 (49.2)
   EPBD 23 (37.7)
   EPBD with EST 8 (13.1)
Number of endoscopic sessions, n (%)
   1 53 (86.9)
   2 or more 8 (13.1)
Use of lithotripsy, n (%) 5 (8.2)
Use of ERBD, n (%) 25 (41)
Adverse events, n (%)
   Bleeding 8 (13.1)
   Post-ERCP pancreatitis 3 (4.9)
   Cholangitis 4 (6.6)
   Perforation 0 (0)
ERCP: endoscopic retrograde cholangiopancreatography; EST: Endoscopic 
sphincterotomy; EPBD: Endoscopic papillary balloon dilation.
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than in the EPBD group (Odds ratio 1.27, 95% confidence 
interval 1.075-1.493, p=0.02). ERCP-related pancreati-
tis occurred in 2 (5.3%) patients in the EST group and 
in one (4.3%) patient in the EPBD group (p=0.55) (Table 
2). Cholangitis occurred in 2 (5.3%) patients in the EST 
group and in 2 (8.7%) in the EPBD group and was not sta-
tistically significant (p=0.63). No procedure-related per-
foration occurred in either group.
DISCUSSION
This study shows that ERCP in the ESRD patients under-
going HD is a reasonable treatment for CBD stone remov-
al. Adverse events were found to be acceptable and the 
overall bile duct clearance rate was high at 96.7%. Inter-
estingly, hemorrhagic adverse events occurred only after 
EST in the present study and not after EPBD (EST 16.7%. 
EST with EPBD 37.5%, EPBD 0%; P=0.02) indicating the 
suitability of ERCP for stone removal in HD patients. On 
the other hand, our results advise against the use of EST 
because of a high associated hemorrhage rate. 
In the present study, ERCP produced satisfactory results 
with respect to the efficacy of stone removal. The over-
all success rate of complete stone retrieval by ERCP was 
96.7% in patients with ESRD on HD, which is compara-
ble with the 90% successful stone removal rate that was 
Table 3. Associations between variables studied and bleeding.
Value
Patient with  
Bleeding  
(n=8)
Patients without  
bleeding  
(n=53) p
Age, mean year (SD) 61.4 (14.6) 70.9 (9.5) 0.11
Gender
   Male/Female 6/2 30/23 0.45
Use of antiplatelet or anticoagulation agent, n (%) 4 (50) 34 (64.2) 0.46
Hemodialysis factors
   Duration of hemodialysis, mean month (SD) 35.13 (57.8) 51.8 (55.7) 0.44
   Time to ERCP from last hemodialysis, mean hour (SD) 27.3 (26.2) 25.9 (17.6) 0.85
   Heparin use during hemodialysis, n (%) 5 (62.5) 38 (71.7) 0.68
Endoscopic factors
   Number of endoscopic sessions, n 1.3 (0.5) 1.1 (0.3) 0.29
   Mechanical lithotripsy, n (%) 1 (12.5) 4 (7.5) 0.52
ERCP procedure, n (%) 0.02
   EST 5 (16.7) 25 (83.3)
   EPBD 0 (0) 23 (100)
   EST+EPBD 3 (37.5) 5 (62.5%)
Hematologic factors
   Hemoglobin, g/dL 10.9 (1.1) 10.3 (1.5) 0.28
   Platelet count, 1000/µ 191.9 (110.7) 186.6 (95.5) 0.83
   Prothrombin time, INR 1.1 (0.3) 1.1 (0.2) 0.89
   Creatinine, mg/dL 5.6 (1.8) 4.9 (3.1) 0.57
   aPTT, sec 28.6 (10.9) 30.9 (13.9) 0.65
ERCP: endoscopic retrograde cholangiopancreatography; EST: Endoscopic sphincterotomy; EPBD: Endoscopic papillary balloon dilation.
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previously reported for CBD stone removal in general 
adult patients (15, 16). This result suggests that ongoing 
HD does not affect the success rate of stone removal by 
ERCP. Although the outcomes of ERCP for CBD stone re-
moval in HD patients have not been sufficiently evaluated, 
one previous study on the clinical outcomes of EPBD in HD 
patients reported a similar result. Takahara et al. conduct-
ed study on 37 patients with bile duct stones who were 
undergoing HD and were treated by EPBD, and reported an 
overall stone removal success rate of 100% and a first ses-
sion success rate of 76% in patients with small stones. (17)
The incidence of ERCP-related adverse events in dialy-
sis patients is expected to be substantially higher than in 
nondialysis patients because of tissue vulnerability and 
a tendency to bleed. However, the incidence of adverse 
events after ERCP for stone removal in patients with 
ESRD on HD has not been previously evaluated. Our re-
sults show an overall adverse event rate of 21.3%, which 
is much higher than the rates reported for the general 
adult population (5 to 9.8%), (12, 13) which may have 
been caused by vulnerability to hemorrhage. In the gener-
al adult population, serious hemorrhage-related EST has 
been reported to occur in up to 2% of ERCP cases (13, 
18). On the other hand, the rate of serious ERCP-related 
hemorrhages (13.1%) in patients with ESRD on HD was 
significantly higher than in the general adult population, 
and this result concurs with previously reported rates (19, 
20). Furthermore, it appears that bleeding tended to be 
more severe in these patients than in the normal CBD 
stone cases, and despite successful treatment, blood 
transfusions were needed. 
The mechanism responsible for excessive hemorrhage in 
patients with ESRD is unclear and may be multifactori-
al. Platelet dysfunctions in the form of impaired platelet 
adhesiveness or altered platelet-vessel-wall interactions 
are believed to play an important role (21). Williams et al. 
found that the rate of severe hemorrhage after ESCP was 
significantly greater in patients undergoing HD (50%) 
than in the normal adult population (1.1%, p<0.001), (19), 
which is consistent with the findings of Nelson et al., (20), 
who suggested a relative risk of hemorrhage of 8.4 among 
hemodialysis patients. However, these studies lack suffi-
cient evidence to demonstrate the nature of any correla-
tion between ERCP-related bleeding risk and ongoing HD 
because the studies had a low number of HD patients. 
In the current study, we analyzed the medical records of 
61 patients with ESRD undergoing HD with CBD stones 
and estimated that this was sufficient to determine the 
risk of post-ERCP hemorrhage in patients with ESRD on 
HD. In addition, we tried to find risk factors of post-ERCP 
hemorrhage in patients with ESRD on HD. Interesting-
ly, post-ERCP hemorrhage occurred only after EST and 
not after EPBD (EST group, 21.1% vs. EPBD group, 0%; 
Table 4. The clinical outcomes and adverse events in the *EST and EPBD groups.
EST (n=38) EPBD (n=23) p
Clinical outcomes, n (%)
   Overall success in stone removal 36 (94.7) 23 (100) 0.52
   Mechanical lithotripsy 3 (7.9) 2 (8.7) 0.63
   Sessions required for complete 
clearance
0.69
   First 32 (84.2) 21 (91.3)
   More than twice 6 (15.8) 2 (8.7)
Adverse events
   Hemorrhage 8 (21.1%) 0 (0%) 0.02
   Pancreatitis 2 (5.3%) 1 (4.3%) 0.55
   Cholangitis 2 (5.3%) 2 (8.7%) 0.63
   Perforation 0 (0%) 0 (0%) 　
EST: Endoscopic sphincterotomy; EPBD: Endoscopic papillary balloon dilation
*EST group includes EST alone and EST plus EPBD cases
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p=0.02), which shows EPBD significantly reduced the risk 
of procedure-related hemorrhage (odds ratio 1.27, 95% 
confidence interval 1.075-1.493, p=0.02). This finding is 
in-line with those of a previous study, (17) in which no 
hemorrhage developed in any of the 33 patients on HD 
who underwent EPBD. The authors concluded that EPBD 
appeared to be safe and effective for bile duct stone ex-
traction in HD patients. In the current study, our analy-
sis of other factors related to hemorrhage identified only 
EST and no contribution from age, gender, antiplatelet 
agent and/or anticoagulant use, hemodialysis factors (in-
cluding heparin use), endoscopic factors or hematologic 
Figure 1. a-d. a) Normal appearance of duodenal ampulla before procedure. b) Minor bleeding after EST. c) Extraction of a brown 
pigment stone after EST. d) Duodenal ampulla at one day after EST, showing copious amounts of blood clots with oozing blood 
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factors. We suppose the impact of EST in HD patients is 
caused by predisposition to or an exacerbation of hemor-
rhage related to associated platelet dysfunctions and the 
activation of fibrinolysis (21, 22). Therefore, we believed 
that EPBD would be a safer procedure than EST for pa-
tients with HD. 
Pancreatitis is the most serious adverse event after ERCP. 
In previous randomized controlled trials in a non-HD set-
ting, the incidence of pancreatitis was reported to be 1.6-
15.7%, (23, 24) and in the present study, the incidence 
of ERCP-related pancreatitis was similar at 4.9% (3/61). 
Therefore, we believe ERCP is a feasible procedure in HD 
patients as well as in non-HD patients in terms of the risk 
of ERCP-related pancreatitis.
The usefulness of EPBD for CBD stone removal is a mat-
ter of considerable debate (25). EPBD is the preferred 
procedure for stone removal in Asia, and has been shown 
to have adverse event rates equivalent to or less than 
those of EST (26, 27). On the other hand, EPBD is rare-
ly performed in the United States because of concerns 
of EPBD-related pancreatitis. However, in the present 
study, ERCP-related pancreatitis was detected in only 
one patient after EPBD, and pancreatitis rates were simi-
lar for the EST (5.3%) and EPBD (4.3%) groups (p=0.55). 
Therefore, we recommend that EPBD be considered the 
first endoscopic option for patients with ESRD on HD be-
cause of its low hemorrhage and similar pancreatitis risks.
This study has certain limitations. First, it is limited by its 
retrospective design and a limited number of cases. Pa-
tients with unsuccessful cholangiography were excluded 
from the current study due to the lack of medical records 
of these patients. Thus, it is possible that the results of 
the current study did not reflect the real clinical condi-
tions of the HD patients who underwent ERCP. In addi-
tion, the occurrence of cholangitis related to ERCP was 
defined on the basis of the Charcot triad. However, this 
triad is not able to differentiate between cholangitis and 
cholecystitis in a retrospective setting. Therefore, the in-
cidence of cholangitis related to ERCP in current study 
has the risk of overestimation. With regard to the risk of 
bleeding, ERCPs were conducted without the discontin-
uation of antiplatelet and anticoagulation agents, and the 
risk factors that might be associated with bleeding, such 
as severity of cholangitis, presence of periampullary di-
verticulum, precut sphincterotomy, uncontrolled cutting 
during sphincterotomy, and stone impaction were not 
evaluated in the current study. Therefore, there is a risk 
that the factors associated with bleeding were not well 
evaluated. Further investigation in a prospective setting 
is needed to confirm the safety of ERCP for patients with 
ESRD undergoing HD. Second, we did not perform long-
term follow-up to determine stone recurrence rates. We 
suggest that an accumulation of cases and long-term 
analysis are needed to confirm the safety and efficacy of 
ERCP in patients with ESRD on HD. Last, there is a risk of 
bias because the selection of patients with EST or EPBD 
was determined by each researcher’s preference. In addi-
tion, the characteristics of stones including size, number, 
and the location of stones were not clear in the current 
study, and the study did not evaluate if these factors af-
fected the clinical outcomes of EST and EPBD. Therefore, 
there is a possibility that our results do not sufficiently 
represent the clinical outcomes of EST and EPBD. 
In conclusion, the present study shows that ERCP is fea-
sible for the treatment of CBD stones in patients with 
ESRD on HD and the rate of adverse event is acceptable. 
Furthermore, we found that EST was significantly relat-
ed to hemorrhagic events and that EPBD significantly 
reduced the risk of hemorrhage and was as effective as 
EST in terms of successful stone removal. Therefore, we 
recommend that EPBD be substituted for EST in patients 
with ESRD on HD.
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